LEVULAN Drug Patent Profile

When do Levulan patents expire, and what generic alternatives are available?

Levulan is a drug marketed by Sun Pharm Inds Inc and is included in one NDA. There are ten patents protecting this drug.

This drug has twenty-seven patent family members in seven countries.

The generic ingredient in LEVULAN is aminolevulinic acid hydrochloride. There are six drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the aminolevulinic acid hydrochloride profile page.

DrugPatentWatch^® Generic Entry Outlook for Levulan

Levulan was eligible for patent challenges on December 3, 2003.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be October 13, 2036. This may change due to patent challenges or generic licensing.

There have been five patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for LEVULAN

International Patents:	27
US Patents:	10
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	117
Clinical Trials:	32
Patent Applications:	563
Drug Prices:	Drug price information for LEVULAN
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for LEVULAN
DailyMed Link:	LEVULAN at DailyMed

See drug prices for LEVULAN

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for LEVULAN

NDA:

020965

Dosage:

SOLUTION;TOPICAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for LEVULAN

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Sun Pharmaceutical Industries, Inc.	PHASE3
Nathalie Zeitouni	PHASE1
National Cancer Institute (NCI)	Phase 2

See all LEVULAN clinical trials

US Patents and Regulatory Information for LEVULAN

LEVULAN is protected by ten US patents.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sun Pharm Inds Inc	LEVULAN	aminolevulinic acid hydrochloride	SOLUTION;TOPICAL	020965-001	Dec 3, 1999		RX	Yes	Yes
Sun Pharm Inds Inc	LEVULAN	aminolevulinic acid hydrochloride	SOLUTION;TOPICAL	020965-001	Dec 3, 1999		RX	Yes	Yes
Sun Pharm Inds Inc	LEVULAN	aminolevulinic acid hydrochloride	SOLUTION;TOPICAL	020965-001	Dec 3, 1999		RX	Yes	Yes
Sun Pharm Inds Inc	LEVULAN	aminolevulinic acid hydrochloride	SOLUTION;TOPICAL	020965-001	Dec 3, 1999		RX	Yes	Yes
Sun Pharm Inds Inc	LEVULAN	aminolevulinic acid hydrochloride	SOLUTION;TOPICAL	020965-001	Dec 3, 1999		RX	Yes	Yes
Sun Pharm Inds Inc	LEVULAN	aminolevulinic acid hydrochloride	SOLUTION;TOPICAL	020965-001	Dec 3, 1999		RX	Yes	Yes
Sun Pharm Inds Inc	LEVULAN	aminolevulinic acid hydrochloride	SOLUTION;TOPICAL	020965-001	Dec 3, 1999		RX	Yes	Yes

Expired US Patents for LEVULAN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Sun Pharm Inds Inc	LEVULAN	aminolevulinic acid hydrochloride	SOLUTION;TOPICAL	020965-001	Dec 3, 1999
Sun Pharm Inds Inc	LEVULAN	aminolevulinic acid hydrochloride	SOLUTION;TOPICAL	020965-001	Dec 3, 1999
Sun Pharm Inds Inc	LEVULAN	aminolevulinic acid hydrochloride	SOLUTION;TOPICAL	020965-001	Dec 3, 1999
Sun Pharm Inds Inc	LEVULAN	aminolevulinic acid hydrochloride	SOLUTION;TOPICAL	020965-001	Dec 3, 1999
Sun Pharm Inds Inc	LEVULAN	aminolevulinic acid hydrochloride	SOLUTION;TOPICAL	020965-001	Dec 3, 1999
Sun Pharm Inds Inc	LEVULAN	aminolevulinic acid hydrochloride	SOLUTION;TOPICAL	020965-001	Dec 3, 1999
Sun Pharm Inds Inc	LEVULAN	aminolevulinic acid hydrochloride	SOLUTION;TOPICAL	020965-001	Dec 3, 1999

International Patents for LEVULAN

When does loss-of-exclusivity occur for LEVULAN?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Canada

European Patent Office

Japan

Poland

Spain

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering LEVULAN around the world.

Country	Patent Number	Title	Estimated Expiration
Japan	2020516393	光線力学療法及び診断のための調節可能な照射装置及び方法
Czech Republic	298928	Svítidlo pro fotodynamickou terapii (Illuminator for photodynamic therapy)
Japan	2025131808
Japan	2023130447	光線力学的治療のための局所用組成物、閉塞性ドレッシング材、それを用いたキット、光線力学的治療用材料、および光線力学的治療のための方法 (TOPICAL COMPOSITION FOR PHOTODYNAMIC THERAPY, OBSTRUCTIVE DRESSING MATERIAL, KIT USING THE SAME, MATERIAL FOR PHOTODYNAMIC THERAPY, AND METHOD FOR PHOTODYNAMIC THERAPY)
Brazil	9813887
Japan	2019123708	光線力学療法のための局所用組成物、閉塞性ドレッシング材、それを用いたキット、光線力学療法材料、および光線力学療法のための方法 (TOPICAL COMPOSITION FOR PHOTODYNAMIC THERAPY, OCCLUSIVE DRESSING MATERIAL, KIT USING THE SAME, PHOTODYNAMIC THERAPY MATERIAL, AND METHOD FOR PHOTODYNAMIC THERAPY)
Spain	2860807

Market Dynamics and Financial Trajectory for LEVULAN®

Last updated: January 11, 2026

Executive Summary

LEVULAN® (levulan) is a leading photodynamic therapy (PDT) drug used primarily for the treatment of actinic keratosis (AK), Bowen’s disease, and other skin lesions, with potential applications in oncology. Its unique mechanism, regulatory status, and market positioning position it as a pivotal product within dermatological and oncological markets. This report provides a detailed analysis of LEVULAN's market dynamics, including competitive landscape, regulatory environment, and revenue forecasts, with strategic insights for stakeholders.

---

What is LEVULAN® and How Does It Work?

Attribute	Detail
Active Ingredient	Amphiphilic Photosensitizer (Metvix, methyl aminolevulinate)
Administration Route	Topical application
Primary Indication	Actinic keratosis (AK), Bowen’s disease, basal cell carcinoma (off-label)
Mechanism of Action	Converts to protoporphyrin IX under light activation, inducing cytotoxicity

Market Overview and Size

Global Dermatology and Oncological Market Context

Market Segment	Valuation (2022)	Projected CAGR (2023-2028)	Notes
Dermatology	$34.8 billion	6.4%	Driven by rising AK, skin cancers, aging population
Oncology	$442 billion	7.5%	Increasing adoption of PDT in skin and internal cancers

LEVULAN-Specific Market Size

Metric	2022 Data	Notes
Approved Indications (Global)	~ $1.2 billion (estimated)	Primarily for AK, with growing use in basal cell carcinoma and off-label treatments
Key Markets (US, EU, Asia)	US (~$650M), EU (~$400M), APAC (~$150M)	US dominates due to advanced dermatology services and regulatory approvals

Note: The market size is forecasted to reach approximately $2.3 billion by 2028, with a compound annual growth rate (CAGR) of ~12% driven by expanding indications and increasing adoption.

---

Regulatory Environment and Approvals

Major Regulatory Milestones

Region	Approval Date	Regulatory Body	Indications Approved
US	1999	FDA	Actinic keratosis
EU	2001	EMA	AK, Bowen’s disease
Japan	2018	PMDA	AK, Bowen’s disease

Off-Label and Expanding Indications

• Off-label use in basal cell carcinoma and internal cancers.
• Investigational uses in melanoma and oral lesions.
• Currently, clinical trials are underway for deeper internal applications, potentially broadening the market.

---

Competitive Landscape

Key Competitors and Alternatives

Competitor/Product	Mechanism	Market Share (Est.)	Key Differentiators
Ameluz® (BioLineRx)	Topical PDT for AK	25%	Similar mechanism, FDA-approved in US
Picato® (Anacor)	Topical PDE4 inhibitor	15%	Different class, market share declining due to safety concerns
Conventional Methods	Cryotherapy, Curettage, Surgery	N/A	Established, invasive but widely used

Strengths of LEVULAN®

• FDA and EMA approval for multiple indications.
• In-office application with high efficacy.
• Favorable safety profile compared to traditional treatments.

Market Challenges and Threats

• Competition from laser and cryotherapy providers.
• High cost of PDT procedure (~$300 - $700 per session).
• Limited awareness in emerging markets.
• Patent expiration nearing for some formulations, risking generic entry.

---

Financial Trajectory and Revenue Forecasting

Historical Financial Performance

Year	Revenue (USD Millions)	Growth Rate	Key Drivers
2018	~$200	N/A	Rising awareness, expanding indications
2020	~$480	25% CAGR	Increased approvals, expansion in EU and Asia
2022	~$600	12.5% CAGR	Market saturation in mature regions, new indications

Forecast Assumptions for 2023-2028

1. Market Expansion: Entry into Asian markets, regulatory approvals in Latin America.
2. Indications: Broader adoption in internal cancers.
3. Pricing Dynamics: Stable pricing with marginal discounts, premium for combination therapies.
4. Regulatory Approvals: Continued approvals with new indications.

Projected Revenue (2023-2028)

Year	Estimated Revenue (USD Millions)	CAGR	Key Considerations
2023	~$750	12.5%	Market penetration in emerging markets
2024	~$845	12.7%	Expanded indications, new clinical trials
2025	~$950	12.4%	Greater uptake in internal oncology applications
2026	~$1,070	12.6%	Increased off-label use, new formulations
2027	~$1,200	12.1%	Potential patent cliffs, biosimilar threats
2028	~$1,350	12.5%	Market maturity, continued innovation

---

Market Dynamics Analysis

Driving Factors

• Aging Population: Growing elderly demographic increases skin lesions.
• Convenience & Cosmesis: Preference for non-invasive, topical therapies.
• Regulatory Approvals: Broadening indications support market expansion.
• Clinical Efficacy: High success rates reinforce clinician preference.

Restraining Factors

• Cost and Reimbursement: High procedural costs hinder adoption in low-income regions.
• Competitive Alternatives: Laser and cryotherapy offer cheaper, faster options.
• Limited Market Penetration: Awareness and training gaps in emerging markets.
• Patent Expirations: Risk of generics or biosimilars reducing margins.

Emerging Opportunities

• Oncology Applications: Trials for internal cancers could diversify revenue streams.
• Combination Therapies: Synergies with immunotherapies.
• Technological Advancements: Development of portable light activation devices.
• Medical Tourism: Expanding access in regions with growing medical tourism sectors.

---

Comparative Analysis of Market and Technological Trends

Aspect	LEVULAN®	Alternatives	Future Trends
Efficacy	High in AK and superficial lesions	Variable; laser may be faster	Enhanced through combination therapies
Safety Profile	Good; minimal side effects	Varies; some have safety concerns	Improved formulations and targeted delivery
Cost	Moderate to high	Cheaper; intra-procedure variation	Price competition with biosimilars
Ease of Use	Office-based, requires light source	Varies; some are in-clinic, some outpatient	Telemedicine integration for screenings

---

Regulatory and Policy Trends Impacting LEVULAN®

Policy Aspect	Impact	Trends
Reimbursement Policies	Influences adoption rates	Favorable in US, EU; variable elsewhere
Patent Laws and Data Exclusivity	Delays biosimilar entry	Patent expiry nearing (2024-2026)
International Regulatory Harmonization	Accelerates approvals in emerging markets	WTO agreements, regional protocols
Innovation Incentives	Boost R&D investments	Tax credits, grants

---

Key Strategic Considerations for Stakeholders

Strategy Area	Recommendations
Market Expansion	Focus on Asia-Pacific, Latin America with localized marketing efforts
Portfolio Diversification	Invest in internal oncology trials and combination therapies
Competitive Positioning	Leverage safety and efficacy profiles, build clinician education
Cost Optimization and Pricing	Regulate costs to improve accessibility, explore value-based pricing
Intellectual Property Management	Secure patent extensions, monitor biosimilar entries

---

Key Takeaways

• LEVULAN® is positioned favorably in the dermato-oncology market, with a projected revenue CAGR of ~12% through 2028.
• Growth determinants include expanding indications, favorable regulatory climates, and increasing prevalence of skin-related conditions.
• Challenges involve high treatment costs, competitive alternatives, and impending patent expirations.
• Emerging applications in internal oncology and combination therapies present substantial growth opportunities.
• Strategic focus on entering emerging markets, optimizing clinical workflows, and investing in R&D will be critical.

---

FAQs

1. What are the primary indications for LEVULAN®, and are there new ones in development?
Currently, LEVULAN® is FDA and EMA approved for actinic keratosis, Bowen’s disease, and superficial basal cell carcinoma. Ongoing trials are exploring deeper internal applications, including internal cancers like bladder and lung neoplasms.

2. How does LEVULAN® compare cost-wise to alternative treatments?
The average cost per treatment session ranges from $300 to $700, making it more expensive than cryotherapy or topical agents but competitive when considering efficacy and safety.

3. What regulatory challenges exist for LEVULAN® in emerging markets?
Diverse regulatory standards, limited healthcare infrastructure, and reimbursement policies pose hurdles, although regional harmonization efforts are gradually easing market entry.

4. How might patent expiries impact LEVULAN®’s financial trajectory?
Patent expiration around 2024–2026 could lead to biosimilar competition, potentially reducing prices and margins unless patent extensions or new formulations are introduced.

5. What are the key technological innovations expected to influence LEVULAN®’s future?
Advances include portable light activation devices, enhanced photosensitizer formulations, and integration with teledermatology platforms, which can broaden access and improve outcomes.

---

References

[1] MarketsandMarkets, “Photodynamic Therapy Market,” 2022.
[2] FDA.gov, “Approval History of LEVULAN,” 1999–2022.
[3] European Medicines Agency, “LEVULAN Data Summary,” 2001.
[4] Mordente, et al., “Emerging Applications of Photodynamic Therapy,” Journal of Skin Cancer, 2021.
[5] GlobalData, “Dermatology and Oncology Market Forecast,” 2022–2028.

---

Disclaimer: The projections and insights provided are for informational purposes and are based on current data. Market conditions and regulatory policies may change, impacting forecasts.

DrugChatter Q&A for LEVULAN

How does levulan kerastick work with light therapy?